Journal of Andrology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Published-Ahead-of-Print April 2, 2009, DOI:10.2164/jandrol.108.007245
Journal of Andrology, Vol. 30, No. 5, September/October 2009
Copyright © American Society of Andrology
DOI: 10.2164/jandrol.108.007245

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
30/5/477    most recent
Author Manuscript (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Traish, A. M.
Right arrow Articles by Guay, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Traish, A. M.
Right arrow Articles by Guay, A.

Review

The Dark Side of Testosterone Deficiency: III. Cardiovascular Disease

ABDULMAGED M. TRAISH*, FARID SAAD{dagger},{ddagger}, ROBERT J. FEELEY* AND ANDRE GUAY§

From the * Department of Biochemistry and Urology, Boston University School of Medicine, Boston, Massachusetts; {dagger} Bayer-Schering Pharma, Men's Healthcare, Berlin, Germany; {ddagger} Gulf Medical College School of Medicine, Ajman, UAE; and the § Department of Endocrinology, Center for Sexual Function, Lahey Clinic, Peabody, Massachusetts.

Correspondence to: Dr Abdulmaged M. Traish, Professor of Biochemistry and Urology, Director, Laboratories for Sexual Medicine, Institute for Sexual Medicine, Boston University School of Medicine, Center for Advanced Biomedical Research, 700 Albany St, W607, Boston, MA 02118 (e-mail: atraish{at}bu.edu).



Abstract

A considerable body of evidence exists suggesting that androgen deficiency contributes to the onset, progression, or both of cardiovascular disease (CVD). The aim of this review is to evaluate the relationships between testosterone (T) deficiency and risk factors of CVD and to discuss the implications of androgen deficiency in men with cardiovascular risk factors. The relationship between androgen deficiency and endothelial function, lipid profiles, inflammatory responses, altered vascular smooth muscle reactivity, and hypertension are discussed with regard to CVD. A comprehensive literature search was carried out with the use of Pub Med from 1980 through 2009, and relevant articles pertinent to androgen deficiency and vascular disease were evaluated and discussed. Low T, whether attributed to hypogonadism or androgen deprivation therapy, in men with prostate carcinoma, produces adverse effects on cardiovascular health. Androgen deficiency is associated with increased levels of total cholesterol, low-density lipoprotein, increased production of proinflammatory factors, and increased thickness of the arterial wall and contributes to endothelial dysfunction. Testosterone supplementation restores arterial vasoreactivity; reduces proinflammatory cytokines, total cholesterol, and triglyceride levels; and improves endothelial function but also might reduce high-density lipoprotein levels. Testosterone is an anabolic hormone with a wide range of beneficial effects on men's health. The therapeutic role of T in men's health, however, remains a hotly debated issue for a number of reasons, including the purported risk of prostate cancer. In view of the emerging evidence suggesting that androgen deficiency is a risk factor for CVD, androgen replacement therapy could potentially reduce CVD risk in hypogonadal men. It should be emphasized, however, that androgen replacement therapy should be done with very thorough and careful monitoring for prostate diseases.

     Key words: Androgen deficiency, endothelial dysfunction, metabolic syndrome




This article has been cited by other articles:


Home page
BloodHome page
C. Lupu, H. Zhu, N. I. Popescu, J. D. Wren, and F. Lupu
Novel protein ADTRP regulates TFPI expression and function in human endothelial cells in normal conditions and in response to androgen
Blood, October 20, 2011; 118(16): 4463 - 4471.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. Dandona and S. Dhindsa
Update: Hypogonadotropic Hypogonadism in Type 2 Diabetes and Obesity
J. Clin. Endocrinol. Metab., September 1, 2011; 96(9): 2643 - 2651.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
J. Kyriazis, I. Tzanakis, K. Stylianou, I. katsipi, D. Moisiadis, A. Papadaki, V. Mavroeidi, S. Kagia, N. Karkavitsas, and E. Daphnis
Low serum testosterone, arterial stiffness and mortality in male haemodialysis patients
Nephrol. Dial. Transplant., September 1, 2011; 26(9): 2971 - 2977.
[Abstract] [Full Text] [PDF]


Home page
J AndrolHome page
S. La Vignera, R. A. Condorelli, E. Vicari, R. D'Agata, and A. E. Calogero
New Immunophenotype of Blood Endothelial Progenitor Cells and Endothelial Microparticles in Patients With Arterial Erectile Dysfunction and Late-Onset Hypogonadism
J Androl, September 1, 2011; 32(5): 509 - 517.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
M. I. Yilmaz, A. Sonmez, A. R. Qureshi, M. Saglam, P. Stenvinkel, H. Yaman, T. Eyileten, K. Caglar, Y. Oguz, A. Taslipinar, et al.
Endogenous Testosterone, Endothelial Dysfunction, and Cardiovascular Events in Men with Nondialysis Chronic Kidney Disease
Clin. J. Am. Soc. Nephrol., July 1, 2011; 6(7): 1617 - 1625.
[Abstract] [Full Text] [PDF]


Home page
Oxford Textbook of Endocrinology and DiabetesHome page
L. J. G. Gooren
9.5.3 Male reproductive health
Oxford Textbook of Endocrinology and Diabetes, July 1, 2011; 2(1): med-9780199235292-chapter - med-9780199235292-chapter.
[Abstract] [Full Text]


Home page
Eur J Heart FailHome page
E. Wehr, S. Pilz, B. O. Boehm, W. Marz, T. Grammer, and B. Obermayer-Pietsch
Low free testosterone is associated with heart failure mortality in older men referred for coronary angiography
Eur J Heart Fail, May 1, 2011; 13(5): 482 - 488.
[Abstract] [Full Text] [PDF]


Home page
J AndrolHome page
B. J. Attardi, B. T. Marck, A. M. Matsumoto, S. Koduri, and S. A. Hild
Long-Term Effects of Dimethandrolone 17{beta}-Undecanoate and 11{beta}-Methyl-19-Nortestosterone 17{beta}-Dodecylcarbonate on Body Composition, Bone Mineral Density, Serum Gonadotropins, and Androgenic/Anabolic Activity in Castrated Male Rats
J Androl, March 1, 2011; 32(2): 183 - 192.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
J. J. Carrero, A. R. Qureshi, A. Nakashima, S. Arver, P. Parini, B. Lindholm, P. Barany, O. Heimburger, and P. Stenvinkel
Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease
Nephrol. Dial. Transplant., January 1, 2011; 26(1): 184 - 190.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
H. S. Haugnes, T. Wethal, N. Aass, O. Dahl, O. Klepp, C. W. Langberg, T. Wilsgaard, R. M. Bremnes, and S. D. Fossa
Cardiovascular Risk Factors and Morbidity in Long-Term Survivors of Testicular Cancer: A 20-Year Follow-Up Study
J. Clin. Oncol., October 20, 2010; 28(30): 4649 - 4657.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S.-H. Chou, Y.-C. Lee, C.-F. Huang, Y.-R. Wang, H.-P. Yu, and Y.-T. Lau
Gender-specific effects of caloric restriction on the balance of vascular nitric oxide and superoxide radical
Cardiovasc Res, September 1, 2010; 87(4): 751 - 759.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
G. Jackson
Testosterone deficiency syndrome (TDS) and the heart
Eur. Heart J., June 2, 2010; 31(12): 1436 - 1437.
[Full Text] [PDF]


Home page
Reproductive SciencesHome page
F. R. Perez-Lopez, L. Larrad-Mur, A. Kallen, P. Chedraui, and H. S. Taylor
Review: Gender Differences in Cardiovascular Disease: Hormonal and Biochemical Influences
Reproductive Sciences, June 1, 2010; 17(6): 511 - 531.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by The American Society of Andrology.